Currently, there are 101.58M common shares owned by the public and among those 99.79M shares have been available to trade.
The company’s stock has a 5-day price change of -28.89% and -42.81% over the past three months. NTLA shares are trading -50.84% year to date (YTD), with the 12-month market performance down to -35.28% lower. It has a 12-month low price of $15.35 and touched a high of $34.87 over the same period. NTLA has an average intraday trading volume of 1.68 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -19.07%, -26.59%, and -37.50% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Intellia Therapeutics Inc (NASDAQ: NTLA) shares accounts for 85.49% of the company’s 101.58M shares outstanding.
It has a market capitalization of $1.52B and a beta (3y monthly) value of 1.77. The earnings-per-share (ttm) stands at -$5.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.72% over the week and 5.90% over the month.
Earnings per share for the fiscal year are expected to decrease by -0.04%, and -2.84% over the next financial year. EPS should grow at an annualized rate of 30.00% over the next five years, compared to -22.30% over the past 5-year period.
Looking at the support for the NTLA, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on February 23, 2024, with the firm’s price target at $136-$32. Canaccord Genuity was of a view on April 13, 2023 that the stock is Buy, while Bernstein gave the stock Outperform rating on March 21, 2023, issuing a price target of $54. BMO Capital Markets on their part issued Outperform rating on March 14, 2023.
